NeuroVRD represents the kind of company we actively seek at Matchplay: one that identifies a critical bottleneck in a large, established market and reimagines it through technology. In high-risk surgeries, preserving nerve function can significantly impact patient outcomes, yet access to intraoperative monitoring remains constrained by specialist availability, cost, and inconsistent delivery. NeuroVRD is tackling this challenge head-on by bringing AI-powered, real-time surgical intelligence directly into the operating room. That vision, combined with strong industry validation and an experienced leadership team, made this an investment opportunity we couldn't ignore.
Why we invested
At MatchPlay, we invest in companies operating where the cost of failure is immediate.
The operating room is one of those environments.
In high-risk surgeries, preserving nerve function is critical to patient outcomes. Intraoperative monitoring is widely accepted as the standard of care.
The issue is not awareness. It’s availability.
The team
NeuroVRD is led by Jeffrey Owen, a pioneer in intraoperative monitoring who has built and scaled this category before.
What stood out to us was not just experience, but perspective. The team understands that the limitation is not clinical knowledge, but how monitoring is delivered, constrained by specialist availability, inconsistent execution, and high-cost service models.
That insight is reflected directly in how NeuroVRD is building its platform.
Our perspective
Surgical innovation has advanced rapidly across robotics, imaging, and precision tools.
But real-time decision intelligence has not kept pace.
Today’s monitoring model is:
- dependent on specialized personnel
- inconsistent across procedures
- limited by cost and availability
As a result, access remains uneven, and outcomes are influenced by variability in execution.
We don’t see this as a clinical gap.
We see it as a delivery model failure.
This sits within a multi-billion dollar surgical monitoring and device ecosystem, where most high-risk procedures still lack consistent monitoring.
What convinced us
NeuroVRD is not improving the existing model. It is replacing it.
The company is building an AI-driven intraoperative monitoring platform that provides real-time feedback directly to surgeons, removing dependence on traditional service-based delivery.
This creates a fundamentally different system:
- monitoring becomes scalable, not resource-constrained
- signal detection becomes consistent, not operator-dependent
- decisions happen in real time, not through delayed interpretation
Incumbents are built around service delivery. NeuroVRD is built around automation. That’s not an upgrade. It’s a different model.
Traditional monitoring relies on human interpretation layered over complex workflows. NeuroVRD uses AI to surface early signals of nerve stress directly to the surgeon, enabling intervention before irreversible damage occurs.
This shifts monitoring from reactive observation to proactive decision support.
What reinforced our conviction was early validation through leading surgical institutions and strong alignment from key opinion leaders across specialties.
Why now
We are at a turning point in surgical care.
Robotics and data systems are transforming how procedures are performed. But intelligence during surgery remains underdeveloped.
At the same time:
- surgical volumes are increasing
- healthcare systems are under pressure to improve outcomes
- cost constraints are forcing a shift away from service-heavy models
As with other industries, systems dependent on specialized human intervention eventually transition to scalable, software-driven infrastructure.
We believe intraoperative monitoring is at that transition point.
Our conviction
We believe the next phase of surgical innovation will be defined by systems that bring real-time intelligence directly into the operating room.
If NeuroVRD succeeds, real-time surgical intelligence won’t be optional. It will be embedded into every high-risk procedure.
NeuroVRD is not building a better version of IONM.
It is building the intelligence layer surgery has been missing.
